The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimated cost of adverse event (AE) management for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with a VEGFR TKI.
 
Jeffrey Thomas Yorio
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte
Speakers' Bureau - OncLive
 
Aviva G. Asnis-Alibozek
Stock and Other Ownership Interests - Advaxis; Gilead Sciences; Nektar
Consulting or Advisory Role - Antios Therapeutics; AstraZeneca; AVEO; Bayer; Sumitomo Dainippon Pharma Oncology
 
Vijay Kasturi
Employment - AVEO; FerGene
Leadership - AVEO; FerGene
Stock and Other Ownership Interests - AVEO
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)